Selected News from Today's FirstWord

Combination of Bristol-Myers Squibb's Yervoy, nivolumab shows promise in early-stage melanoma trial

Bristol-Myers Squibb released preliminary data ahead of the ASCO meeting from an early-stage trial, demonstrating that the combination of Yervoy (ipilimumab) and the investigational PD-1 receptor Full story

Also in the News

FirstWord Dossier Reports
www.fwreports.com

**NEW** The complete list of FirstWord Dossier reports can be found at www.fwreports.com

FirstWord Dossier reports provide insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date and actionable intelligence ... reports that deliver information vital for competitive advantage.

Click here to see our recent reports.

Most Read Stories in the Past Week

Recent Reports